Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate ADMA Biologics Inc before investing.

In this article, we go over a few key elements for understanding ADMA Biologics Inc’s stock price such as:

• ADMA Biologics Inc’s current stock price and volume
• Why ADMA Biologics Inc’s stock price changed recently
• Upgrades and downgrades for ADMA from analysts
• ADMA’s stock price momentum as measured by its relative strength

About ADMA Biologics Inc (ADMA)

Before we jump into ADMA Biologics Inc’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.

Want to learn more about ADMA Biologics Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about ADMA Biologics Inc.

ADMA Biologics Inc’s Stock Price as of Market Close

As of August 23, 2024, 4:00 PM, CST, ADMA Biologics Inc’s stock price was $18.40.

ADMA Biologics Inc is up 5.14% from its previous closing price of $17.50.

During the last market session, ADMA Biologics Inc’s stock traded between $17.40 and $17.99. Currently, there are 232.42 million shares of ADMA Biologics Inc stock available for purchase.

ADMA Biologics Inc’s price-earnings (P/E) ratio is currently at 124.5, which is high compared to the Pharmaceuticals industry median of 25.8. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

ADMA Biologics Inc Stock Price History

ADMA Biologics Inc’s (ADMA) price is currently up 49.84% so far this month.

During the month of August, ADMA Biologics Inc’s stock price has reached a high of $18.43 and a low of $10.21.

Over the last year, ADMA Biologics Inc has hit prices as high as $18.43 and as low as $3.06. Year to date, ADMA Biologics Inc’s stock is up 374.23%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused ADMA Biologics Inc Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of August 22, 2024, there were 0 analysts who downgraded ADMA Biologics Inc’s stock and 3 analysts who upgraded over the last month.

Additionally, you'll want to evaluate ADMA Biologics Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on ADMA Biologics Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

ADMA Biologics Inc’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about ADMA Biologics Inc (ADMA) by visiting AAII Stock Evaluator.

Relative Price Strength of ADMA Biologics Inc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of August 22, 2024, ADMA Biologics Inc has a weighted four-quarter relative price strength of 47.73%, which translates to a Momentum Score of 98 and is considered to be Very Strong.

Want to learn more about how ADMA Biologics Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

ADMA Biologics Inc Stock Price: Bottom Line

As of August 23, 2024, ADMA Biologics Inc’s stock price is $18.40, which is up 5.14% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like ADMA Biologics Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.